NRIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nurix Therapeutics Inc (NRIX) is not a strong buy for a beginner, long-term investor at this moment. While the stock has positive analyst sentiment and potential long-term catalysts, the lack of immediate trading signals, neutral insider and hedge fund activity, and technical indicators suggesting limited short-term upside make it prudent to hold off on investing right now.
The MACD is slightly positive but contracting, RSI is neutral at 34.419, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 14.787), but there is no strong momentum for upward movement.
Analysts have raised price targets recently, with Piper Sandler, Stifel, and H.C. Wainwright targeting $32-$35, citing progress in clinical trials and pipeline development. Morgan Stanley upgraded the stock to Overweight, highlighting a higher probability of success for its drug pipeline.
No significant news or immediate catalysts in the short term. Stock trend analysis suggests a 70% chance of short-term declines (-1.12% in the next day, -3.92% in the next week, -5.97% in the next month).
In Q4 2025, revenue grew 2.21% YoY to $13.58M, and net income improved by 33.60% YoY to -$78.22M. EPS increased by 9.33% YoY to -0.82. While the gross margin remains strong at 100%, the company is still unprofitable.
Analysts are broadly positive, with multiple firms raising price targets and maintaining Buy/Overweight ratings. However, they note that significant catalysts are expected in 2027, making 2026 a transitional year with limited upside in the near term.
